Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Days Payable is 94.98 as of Mar. 2026, which is 33% below its 10-year median of 142.40. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Niagen Bioscience ranks worse than 54.07% on this metric.
The historical rank and industry rank for Niagen Bioscience's Days Payable or its related term are showing as below:
FRA:OCD1'
s Days Payable Range Over the Past 10 Years
Min: 76.27 Med: 142.4 Max: 197.52
Current: 95.79
During the past 13 years, Niagen Bioscience's highest Days Payable was 197.52. The lowest was 76.27. And the median was 142.40.
FRA:OCD1's Days Payable is ranked worse than 54.07% of 701
companies
in the Biotechnology industry
Industry Median: 113.36
vs FRA:OCD1: 95.79
Niagen Bioscience's Days Payable
increased
from Mar. 2025 (79.52) to Mar. 2026 (94.98).
It may suggest that Niagen Biosciencedelayed paying its suppliers.
Niagen Bioscience Days Payable Related Terms
Niagen Bioscience Days Payable Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Days Payable Comparison
For the Biotechnology subindustry, Niagen Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Niagen Bioscience's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a Days Payable of 94.98 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Niagen Bioscience and its competitors. This is 33% below median its historical median of 142.40. Over the past decade, Niagen Bioscience's Days Payable has ranged from 76.27 to 197.52. According to the industry distribution chart, Niagen Bioscience ranks #379 out of 701 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Niagen Bioscience's Days Payable too high?
Niagen Bioscience's current Days Payable of 94.98 is 33% below median its 10-year median of 142.40. Over the past 10 years, this metric has ranged from a low of 76.27 to a high of 197.52. The Biotechnology industry median Days Payable is 113.36. Niagen Bioscience's value of 94.98 is 16.2% below this industry median. Based on the distribution chart, Niagen Bioscience ranks #379 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Days Payable compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #379 out of 701 companies for Days Payable. This places Niagen Bioscience in the lower half of its industry. The industry median Days Payable is 113.36. Niagen Bioscience's value of 94.98 is 16.2% below this benchmark. Historically, Niagen Bioscience's own Days Payable has ranged from 76.27 to 197.52 over the past decade. While the company's 10-year median is 142.40 vs. the industry median of 113.36, Niagen Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Days Payable of 94.98 is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Days Payable is 94.98, which is 33% below median its own 10-year median of 142.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Days Payable is 94.98, which is 33% below median its 10-year median of 142.40 and 16.2% below the Biotechnology industry median of 113.36. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Days Payable is 94.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Days Payable: 94.98 (33% below median its 10-year median of 142.40)
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
Industry Position: 16.2% below the Biotechnology median (#379 of 701)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
